Bain Capital Acquires Substantial Equity Interest in Brazil’s Healthtech Bionexo

Bain Capital announced on Friday, 15, the purchase of 43% of Brazilian healthtech Bionexo for $70 Million

American investment Bain Capital announced on Friday, 15, the purchase of 43% of Brazilian healthtech Bionexo in a transaction for the amount of $70 million that also makes Bain Capital the main shareholder of the software company.

In addition to the initial capital, Bain Capital committed to injecting about $20 million into the company in the next two years. With post money, secondary and long-term investments, the company should be valued at BRL $1,1 billion.

After the completion of the acquisition of the shares and following secondary investments, Bain Capital will hold 43% of the company’s equity, but the control — and the rest of the shares — will remain with Mauricio De Lázzari Barbosa (founder of Bionex) through its holding company Apus Participações and other investor Prisma Bazar

Bionexo is a technology company founded in 2000 and has more than 500 employees in four countries and integrates technology in the management of processes in the health area.

The Esquires

Pinheiro Guimarães Advogados acted as legal counsel to Bionexo and its shareholders Mauricio Barbosa, Prisma Capital (Brasil), Temasek and minority shareholders. Pinheiro Guimarães’s deal team was led by partners Francisco Pinheiro Guimaraes, Bernardo Bulhões-Arieira and attorneys Bernardo Romano Teixeira and Julia Machado Barreto.

Pinheiro Neto Advogados acted as legal counsel to Bain Capital. The firm’s team was led by partner Carlos Eduardo Azevedo and associate Mariana Magalhães Lobato.

Kirkland & Ellis also acted as legal counsel to Bain Capital with partner Chris Elder and associate Neil Vohra.